Report

Global Psoriasis Therapeutics Market Size study & Forecast, by Drug Class, Molecule Type, and by Route of Administration and Regional Analysis, 2022-2029

  • Publish Date: Nov,2022
  • Report ID: 3-2-1180
  • Page : 200
  • Report Type : PDF (Email)
Global Psoriasis Therapeutics Market is valued approximately USD XX billion in 2021 and is anticipated to grow with a healthy growth rate of more than XX% over the forecast period 2022-2029. Psoriasis is a type of skin disorders which causes skins cells to replace more quickly than normal. Psoriasis is associated with immune system and most commonly occurs on knees, elbows, trunk, and scalp. The increasing incidences of Psoriasis disease and rising awareness towards different treatment options available as well as strategic initiatives from leading market players are key factors accelerating the market growth.

According to National Psoriasis Foundation, USA - as of 2020, around 8 million individuals in the United States are affected by Psoriasis. In addition, around 125 million people worldwide suffers from Psoriasis, witnessing for over 2 to 3 percent of the global population. Moreover, as per World Health Organization (WHO) estimates - approximately 100 million individuals worldwide are affected by Psoriasis. Also, rising healthcare infrastructure in emerging economies and increasing R&D activities in pharmaceuticals sector would create lucrative growth prospectus for the market over the forecast period. However, high treatment cost associated with Psoriasis treatment and health risks associated with medications impede the market growth throughout the forecast period of 2022-2029.

The key regions considered for the Global Psoriasis Therapeutics Market study includes Asia Pacific, North America, Europe, Latin America, and Rest of the World. North America is the; leading region in terms of market share owing to presence of leading market players as well as increasing prevalence of Psoriasis in the region. Whereas Asia Pacific is expected to grow significantly during the forecast period, owing to factors such as rising pharmaceuticals sector as well as increasing incidences of skin disorders in the region.

Major market players included in this report are:

Astellas Pharma Inc.

AstraZeneca plc

Boehringer Ingelheim GmbH

F. Hofffmann-La Roche

GlaxoSmithKline plc

Merck and Co., Inc.

Valeant Pharmaceuticals International, Inc.

Biocon Limited

Eli Lilly and Company

G and W Laboratories Inc.